FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568690535> ?p ?o ?g. }

• W2568690535 endingPage "e0005281" @default.
• W2568690535 startingPage "e0005281" @default.
• W2568690535 abstract "The leishmanicidal action of tricyclic antidepressants has been studied and evidences have pointed that their action is linked to inhibition of trypanothione reductase, a key enzyme in the redox metabolism of pathogenic trypanosomes. Cyclobenzaprine (CBP) is a tricyclic structurally related to the antidepressant amitriptyline, differing only by the presence of a double bond in the central ring. This paper describes the effect of CBP in experimental visceral leishmaniasis, its inhibitory effect in trypanothione reductase and the potential immunomodulatory activity.In vitro antileishmanial activity was determined in promastigotes and in L. infantum-infected macrophages. For in vivo studies, L. infantum-infected BALB/c mice were treated with CBP by oral gavage for five days and the parasite load was estimated. Trypanothione reductase activity was assessed in the soluble fraction of promastigotes of L. infantum. For evaluation of cytokines, L. infantum-infected macrophages were co-cultured with BALB/c splenocytes and treated with CBP for 48 h. The supernatant was analyzed for IL-6, IL-10, MCP-1, IFN-γ and TNF-α. CBP demonstrated an IC50 of 14.5±1.1μM and an IC90 of 74.5±1.2 μM in promastigotes and an IC50 of 12.6±1.05 μM and an IC90 of 28.7±1.3 μM in intracellular amastigotes. CBP also reduced the parasite load in L. infantum-infected mice by 40.4±10.3% and 66.7±10.5% in spleen at 24.64 and 49.28 mg/kg, respectively and by 85.6±5.0 and 89.3±4.8% in liver at 24.64 and 49.28mg/kg, after a short-term treatment. CBP inhibited the trypanothione reductase activity with a Ki of 86 ± 7.7 μM and increased the ROS production in promastigotes. CBP inhibited in 53% the production of IL-6 in infected macrophages co-culture.To the best of our knowledge, this study is the first report of the in vivo antileishmanial activity of the FDA-approved drug CBP. Modulation of immune response and induction of oxidative stress in parasite seem to contribute to this efficacy." @default.
• W2568690535 created "2017-01-13" @default.
• W2568690535 creator A5006087404 @default.
• W2568690535 creator A5008833161 @default.
• W2568690535 creator A5016996245 @default.
• W2568690535 creator A5025987777 @default.
• W2568690535 creator A5027362621 @default.
• W2568690535 creator A5033551689 @default.
• W2568690535 creator A5041531713 @default.
• W2568690535 creator A5048825035 @default.
• W2568690535 creator A5050820001 @default.
• W2568690535 creator A5082616055 @default.
• W2568690535 creator A5085775380 @default.
• W2568690535 date "2017-01-03" @default.
• W2568690535 modified "2023-10-18" @default.
• W2568690535 title "Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice" @default.
• W2568690535 cites W1518803084 @default.
• W2568690535 cites W1823258013 @default.
• W2568690535 cites W1968238739 @default.
• W2568690535 cites W1972323962 @default.
• W2568690535 cites W1975159342 @default.
• W2568690535 cites W2016418074 @default.
• W2568690535 cites W2023356380 @default.
• W2568690535 cites W2024187667 @default.
• W2568690535 cites W2025073184 @default.
• W2568690535 cites W2025895864 @default.
• W2568690535 cites W2026601658 @default.
• W2568690535 cites W2034857725 @default.
• W2568690535 cites W2035591436 @default.
• W2568690535 cites W2051444452 @default.
• W2568690535 cites W2059356232 @default.
• W2568690535 cites W2062941476 @default.
• W2568690535 cites W2067912653 @default.
• W2568690535 cites W2075224137 @default.
• W2568690535 cites W2100245320 @default.
• W2568690535 cites W2116717421 @default.
• W2568690535 cites W2116930605 @default.
• W2568690535 cites W2121836743 @default.
• W2568690535 cites W2132950549 @default.
• W2568690535 cites W2198907191 @default.
• W2568690535 doi "https://doi.org/10.1371/journal.pntd.0005281" @default.
• W2568690535 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5234845" @default.
• W2568690535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28045892" @default.
• W2568690535 hasPublicationYear "2017" @default.
• W2568690535 type Work @default.
• W2568690535 sameAs 2568690535 @default.
• W2568690535 citedByCount "15" @default.
• W2568690535 countsByYear W25686905352017 @default.
• W2568690535 countsByYear W25686905352018 @default.
• W2568690535 countsByYear W25686905352019 @default.
• W2568690535 countsByYear W25686905352020 @default.
• W2568690535 countsByYear W25686905352021 @default.
• W2568690535 countsByYear W25686905352023 @default.
• W2568690535 crossrefType "journal-article" @default.
• W2568690535 hasAuthorship W2568690535A5006087404 @default.
• W2568690535 hasAuthorship W2568690535A5008833161 @default.
• W2568690535 hasAuthorship W2568690535A5016996245 @default.
• W2568690535 hasAuthorship W2568690535A5025987777 @default.
• W2568690535 hasAuthorship W2568690535A5027362621 @default.
• W2568690535 hasAuthorship W2568690535A5033551689 @default.
• W2568690535 hasAuthorship W2568690535A5041531713 @default.
• W2568690535 hasAuthorship W2568690535A5048825035 @default.
• W2568690535 hasAuthorship W2568690535A5050820001 @default.
• W2568690535 hasAuthorship W2568690535A5082616055 @default.
• W2568690535 hasAuthorship W2568690535A5085775380 @default.
• W2568690535 hasBestOaLocation W25686905351 @default.
• W2568690535 hasConcept C136764020 @default.
• W2568690535 hasConcept C150903083 @default.
• W2568690535 hasConcept C185592680 @default.
• W2568690535 hasConcept C203014093 @default.
• W2568690535 hasConcept C207001950 @default.
• W2568690535 hasConcept C2775993617 @default.
• W2568690535 hasConcept C2776555147 @default.
• W2568690535 hasConcept C2778689377 @default.
• W2568690535 hasConcept C2781092759 @default.
• W2568690535 hasConcept C2781257258 @default.
• W2568690535 hasConcept C41008148 @default.
• W2568690535 hasConcept C71928629 @default.
• W2568690535 hasConcept C86803240 @default.
• W2568690535 hasConcept C8891405 @default.
• W2568690535 hasConcept C98274493 @default.
• W2568690535 hasConcept C98319499 @default.
• W2568690535 hasConceptScore W2568690535C136764020 @default.
• W2568690535 hasConceptScore W2568690535C150903083 @default.
• W2568690535 hasConceptScore W2568690535C185592680 @default.
• W2568690535 hasConceptScore W2568690535C203014093 @default.
• W2568690535 hasConceptScore W2568690535C207001950 @default.
• W2568690535 hasConceptScore W2568690535C2775993617 @default.
• W2568690535 hasConceptScore W2568690535C2776555147 @default.
• W2568690535 hasConceptScore W2568690535C2778689377 @default.
• W2568690535 hasConceptScore W2568690535C2781092759 @default.
• W2568690535 hasConceptScore W2568690535C2781257258 @default.
• W2568690535 hasConceptScore W2568690535C41008148 @default.
• W2568690535 hasConceptScore W2568690535C71928629 @default.
• W2568690535 hasConceptScore W2568690535C86803240 @default.
• W2568690535 hasConceptScore W2568690535C8891405 @default.
• W2568690535 hasConceptScore W2568690535C98274493 @default.
• W2568690535 hasConceptScore W2568690535C98319499 @default.

• next